110
Participants
Start Date
April 30, 2014
Primary Completion Date
February 28, 2015
Study Completion Date
March 31, 2015
Isosorbide Mononitrate
"Dispense phase 1 study drug:~Weeks 1 and 2: No study drug (baseline) Week 3: 30 mg ISMN Week 4: 60 mg ISMN Weeks 5 and 6: 120 mg ISMN~Dispense phase-2 study drug:~Weeks 7 and 8: No study drug (washout) Week 9: 30 mg ISMN Week 10: 60 mg ISMN Weeks 11 and 12: 120 mg ISMN"
Placebo
"Dispense phase 1 study drug:~Weeks 1 and 2: No study drug (baseline) Week 3: 30 mg Placebo Week 4: 60 mg Placebo Weeks 5 and 6: 120 mg Placebo~Dispense phase-2 study drug:~Weeks 7 and 8: No study drug (washout) Week 9: 30 mg Placebo Week 10: 60 mg Placebo Weeks 11 and 12: 120 mg Placebo"
Lancaster General Hospital, Lancaster
University of Pennsylvania Health System, Philadelphia
Jefferson Medical College, Philadelphia
Temple University Hospital, Philadelphia
Christiana Care Health Services, Newark
Johns Hopkins Hospital, Baltimore
Duke University Medical Center, Durham
Emory University School of Medicine, Atlanta
University Hospitals Case Medical Center, Cleveland
Metro Health System, Cleveland
Cleveland Clinic Foundation, Cleveland
Mayo Clinic, Rochester
Northwestern University, Chicago
Washington University School of Medicine, St Louis
Michael E Debakey VA Medical Center, Houston
University of Utah Hospitals and Clinics, Salt Lake City
V.A. Medical Center, Salt Lake City
Tufts Medical Center, Boston
Massachusetts General Hospital, Boston
Brigham and Women's Hospital, Boston
Boston V.A. Healthcare System, West Roxbury
The University of Vermont - Fletcher Allen Health Care, Burlington
Collaborators (1)
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Mayo Clinic
OTHER
University of Vermont
OTHER
Adrian Hernandez
OTHER